Australian Other Utilities Stock News

ASX:PNV
ASX:PNVMedical Equipment

Why PolyNovo (ASX:PNV) Is Up 14.6% After Reporting Strong Annual Profit and Revenue Growth

PolyNovo Limited recently announced its full-year results for the period ended June 30, 2025, reporting revenue of A$129.19 million compared to A$104.76 million a year earlier and net income of A$13.21 million, up from A$5.3 million last year. Strong growth in both revenue and net income marks a significant improvement in PolyNovo's financial performance, reflected in higher basic and diluted earnings per share for the period. We'll examine how PolyNovo's substantial boost in annual net...
ASX:DUG
ASX:DUGSoftware

DUG Technology (ASX:DUG) Is Down After Swing to Loss—Is the Growth Narrative at Risk?

DUG Technology Ltd recently announced full-year results for the period ended June 30, 2025, reporting sales of US$62.58 million and a net loss of US$3.89 million, reversing a net profit from the prior year. The latest figures also highlight a shift in basic earnings per share from a US$0.0234 profit last year to a US$0.0301 loss this year, signaling a significant earnings deterioration. We’ll explore how the swing from net profit to net loss could challenge DUG Technology’s investment...
ASX:SIG
ASX:SIGHealthcare

Sigma Healthcare (ASX:SIG) Faces New Leadership—What Does This Mean for Its Integration Strategy?

Sigma Healthcare Limited recently announced full-year earnings results, reporting sales of A$6.00 billion and net income of A$529.91 million, alongside key executive changes including the resignation of its Group CFO and several leadership reassignments. The combination of leadership transitions and earnings outcomes highlights a period of transformation for Sigma, as it continues integrating operations following its merger with Chemist Warehouse Group. Next, we'll examine how these...
ASX:TLX
ASX:TLXBiotechs

Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter

Telix Pharmaceuticals (ASX:TLX) saw its share price drop 24% last week following regulatory setbacks. The decline was driven by the FDA's issuance of a Complete Response Letter, highlighting deficiencies in Telix's Biologics License Application for TLX250-CDx. This regulatory challenge necessitates manufacturing and data improvements before resubmission. While the broader market experienced a tech-led downturn, Telix's drop contrasts with this trend, largely reflecting concerns specific to...